World Congress on Cancers of the Skin 2018
17 August 2018
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world. Coming together at the ICC in Sydney, it has been an insightful and educational Congress relating to skin cancer and melanoma.
A key feature evident throughout all presentations was the changing landscape relating to melanoma, and how far diagnosis, treatment and education have come. The exponential shift in melanoma survival rates over the last decade is reflective of the global melanoma research effort, however there remains much work still to be done.
Associate Professor Matt Carlino chaired the morning session, Local and Systemic Management of Advanced Melanoma, which included presentations on radiotherapy from Professor Angela Hong, and surgery from Associate Professor Robyn Saw and Professor John Thompson AO. Professor Thompson identified that while surgery has a changing place in melanoma treatment, it still cures 85% of Stage I & II disease. Surgery is not considered the preferred option for advanced melanoma patients, with immunotherapy and targeted therapy proving to be more effective.
Associate Professor Matt Carlino explained the issues surrounding targeted therapy and immunotherapy, and highlighted toxicity as one of the primary concerns of the treatments. The Congress was told, however, that these treatments are changing people’s lives and represent a huge step forward in increasing survival rates in advanced patients.
A key focus of the Congress was a session on Primary Prevention of Skin Cancer, where Dr Annika Smith and Associate Professor Anne Cust argued the importance of sunscreen and dispelled sunscreen myths citing accurate studies such as the ‘Primary Melanoma Project’, ‘The Vancouver Trial’, ‘The Nambour Trial’, as well randomised control trials. A key point emphasised was that use of sunscreen does not cause Vitamin D deficiencies. Delegates were advised that people should not deliberately expose themselves to the sun as incidental exposure is sufficient for Vitamin D levels. Sunscreen quantity and application were also highlighted as crucial.
Clinical Professor of Dermatology Darrell Rigel travelled from New York University Langone Medical Center to discuss US studies relating to sunscreen and melanoma prevention.
“The problem surrounding sunscreen application is simply that people aren’t using enough,” he said. Professor Rigel suggests that lack of cosmetic appeal is a major reason why people are avoiding sunscreen. “The best public health message is use a combination of protection; sunscreen and shade,” he said.
The afternoon session of Management of High Risk Early Stage Melanoma was chaired by Dr Alex Menzies and featured an entire MIA cohort with presentations from Professor Richard Scolyer, Professor Andrew Spillane, Dr Alexander Menzies and Professor Georgina Long.
Topics covered included staging guidelines, sentinel node biopsy, and adjuvant and neoadjuvant therapies. Professor Long emphasised the exciting time in the neoadjuvant therapy space with evidence suggesting drug therapy works better when a patient has an active tumour, rather than after the tumour has been surgically removed.
The WCCS has been an overwhelming success, with many brilliant minds banding together with the overall goal of better understanding skin cancer and melanoma, and ultimately better patient outcomes.
If you're a health professional and interested in taking your melanoma knowledge to the next level, check out our Melanoma Education Portal here.
Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.
It’s time again to say thank you to our amazing community fundraisers!
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.
It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.
MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.
Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.
Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.
Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.
It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.
They are a formidable team - in work and in play
This week, Melanoma Institute Australia hosted the first of six
Federal government urged
We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!
Lauren O'Brien tells us why she's running for a cause close to her heart